RealFeedApp Patent protection for zervimesine runs to 2045
Cognition Therapeutics received a US patent for a novel crystalline form of zervimesine, extending protection to 2045. FDA approval could allow an additional five-year extension.
- Field
- drugs and trials
- What they did
- Cognition Therapeutics received a US patent for a new crystalline form of the drug zervimesine, with protection extending to 2045.
- Why it matters
- The new crystal structure improves the drug's pharmaceutical and physicochemical profile, making it better suited for large-scale manufacturing and potentially allowing for an additional five-year patent extension.
#zervimesine#patent#lewy body disease#cognition therapeutics
